Ketoconazole enantiomer in humans
View Patent ↗Treatment of patients with the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.
1. A method of reducing C-reactive protein levels in a patient in need of such reduction, comprising administering a daily dose of a ketoconazole composition comprising 200 mg to 600 mg of a 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said patient.
2. The method of claim 1 , further comprising identifying or diagnosing the patient as having elevated plasma C-reactive protein and in need of reduction of systemic inflammation.
3. The method of claim 2 , wherein the patient has a plasma C-reactive protein level greater than 3.0 mg/L.
4. The method of claim 2 , wherein the patient has a plasma C-reactive protein level greater than 5.0 mg/L.
5. The method of claim 1 , wherein the patient is diabetic.
6. The method of claim 1 , wherein the patient is diagnosed with metabolic syndrome.
7. The method of claim 1 , wherein the daily dose of the ketoconazole composition is 200 mg to 400 mg of the 2S,4R ketoconazole enantiomer.
8. The method of claim 1 , wherein the ketoconazole content of the composition is more than 98% of the 2S,4R ketoconazole enantiomer.
9. The method of claim 1 , wherein the patient has elevated C-reactive protein levels in plasma.
10. A method of reducing systemic inflammation in a patient in need thereof comprising administering a daily dose of a ketoconazole composition comprising 200 mg to 600 mg of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to said patient.
11. The method of claim 10 , wherein the daily dose of the ketoconazole composition is 200 mg to 400 mg of the 2S,4R ketoconazole enantiomer.
12. The method of claim 10 , wherein the ketoconazole content of the composition is more than 98% of the 2S,4R ketoconazole enantiomer.
13. The method of claim 10 , wherein the patient has elevated C-reactive protein levels in plasma.
14. The method of claim 10 , further comprising identifying or diagnosing the patient as having elevated plasma C-reactive protein and in need of reduction of systemic inflammation.
15. The method of claim 10 , wherein the patient has a plasma C-reactive protein level greater than 3.0 mg/L.
16. The method of claim 10 , wherein the patient has a plasma C-reactive protein level greater than 5.0 mg/L.
17. The method of claim 10 , wherein the patient is diabetic.
18. The method of claim 10 , wherein the patient is diagnosed with metabolic syndrome.